Defense World • Jan 11, 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO - Get Free Report) CEO Leon Moulder, Jr. purchased 20,000 shares of the business's stock in a transaction on Friday, January 9th. The shares were acquired at an ave...
Defense World • Jan 11, 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO - Get Free Report) CEO Leon Moulder, Jr. purchased 30,000 shares of the stock in a transaction that occurred on Thursday, January 8th. The stock was bought at an av...
Defense World • Jan 11, 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO - Get Free Report) CEO Leon Moulder, Jr. bought 50,000 shares of the firm's stock in a transaction on Wednesday, January 7th. The shares were bought at an average c...
Benzinga • Jan 10, 2026
The Benzinga Stock Whisper Index highlights five stocks seeing stronger than normal interest from readers and looks at the potential catalysts driving the attention.
PRNewsWire • Jan 08, 2026
NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised to co...
PRNewsWire • Jan 08, 2026
NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised to co...
Seeking Alpha • Jan 06, 2026
Zenas BioPharma, Inc. (ZBIO) Discusses Positive Phase 3 INDIGO Trial Results for Obexelimab in IgG4-Related Disease Transcript
GlobeNewsWire • Jan 06, 2026
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. (“Zenas” or the “Company”) (NASDAQ: ZBIO). Such investors are advised ...
Zacks Investment Research • Jan 06, 2026
Zenas BioPharma tanks nearly 52% despite positive INDIGO study data where obexelimab cut IgG4-RD flare risk by 56% and met all key endpoints.
Benzinga • Jan 06, 2026
Zenas BioPharma (NASDAQ: ZBIO) shares fell more than 50% in the last trading session following the release of Phase 3 results for obexelimab in patients with immunoglobulin G4-related disease (IgG4-RD...
Seeking Alpha • Jan 06, 2026
Zenas BioPharma remains a 'Strong Buy' after Obexelimab met the phase 3 INDIGO primary endpoint in IgG4-RD, despite a sharp stock decline. The company's pipeline is advancing with Orelabrutinib, a pot...
Defense World • Jan 06, 2026
Zenas BioPharma (NASDAQ: ZBIO) reported top-line results from its registrational phase III INDIGO trial evaluating obexelimab for immunoglobulin G4-related disease (IgG4-RD), saying the study met its ...
Benzinga • Jan 05, 2026
Zenas BioPharma Inc. (NASDAQ: ZBIO) stock is trading lower on Monday after the company released results from the Phase 3 INDIGO trial of obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD).
PRNewsWire • Jan 05, 2026
NEW YORK, Jan. 5, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Zenas BioPharma, Inc. (NASDAQ: ZBIO) on behalf of the company's shareholders. The investigation seeks...
Reuters • Jan 05, 2026
Zenas BioPharma said on Monday its experimental drug cut the risk of disease flare-ups in a late-stage study of patients with a rare immune system-related condition that can damage organs over time.
GlobeNewsWire • Jan 05, 2026
- Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD flare -